CategoryArchive

A little more early hard hitting data…same answer!

After this weekends post you said “How much more “hit it hard and early” evidence do we need before neuros actually begin to adopt this and abandon the escalation strategy?“ I suspect abit more evidence, which they need to read However, one option could be to keep the escalation approach and just avoid using the CRAB drugs etc. The advantage of early effective treatment has been shown...

The 1st anti-plasma cell drug in MS. What should you ask?

SIZOMUS is a short name for “Safety of IxaZOmib targeting plasma cells in MUltiple Sclerosis” I first became the study Clinical Research Fellow on the “SIZOMUS” clinical trail last year. Instantly my brain filled up with questions. I thought I’d go straight to the horse’s mouth for the answers and sought out the two lead study investigators – Prof...

Times are Changing. People are getting B cell tinted glasses to try and explain MS

Our favourite saying has been saying “Its behind you” because when you dont know where you are looking you might not look in the right place….and the big bag cat with a club is behind you compared to the cute little kitties in fronto fo you. In the time of street light science we have been looking at the T cell….Drip, Drip, Drip and we have been making the case that...

Get ready for the flood-gates on papers about poor vaccine responses and B cell inhibition… The Redcoats are coming.

This saying was said (Paul Revere) when the British (soldiers wearing red) arriving in USA Israel got off to a flying start with their vaccination programme, and then the UK got out of the starting blocks quickly. We would know about the effect of MS drugs on COVID-19 if the second dose of vaccine was at 3-4weeks. However, in stepped the Joint vaccinations committee to throw away the purpose of...

The Match

No I am not talking about football. There is a lot of talk about whether smouldering lesions are something different, where their origins may be something other than immune attack. Whilst I have no problem with this, based on histology by the pathologists they accumulate over time. Smouldering lesions are lesions with microglial edge There are more smouldering lesions evident in progression Now...

MD’s Saturday COVID lunch

Learning from other coniditons. Anti-CD20 increases COVID-19 risks Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol 2021 Myasthenia is a conditon associated with antibodies against the junction between the muscle and the peripheral nerves and this has been treated with...

Can rheumatologists stop causing demyelinating disease?

Hello, I am Charalambos Hadjicharalambous, a medical student at Barts and the London School of Medicine and Dentistry working with Dr Gnanapavan (aka NDG) and Prof Baker (aka Mouse Doctor). In my spare time during the COVID-19 pandemic, I have been helping the BartsMS team with their COVID-19 studies. I am writing here to discuss an article that we’ve written detailing a potential rare link...

Gunfight at the OK COVID-19 Coral..Get Shot or should I say Get a Shot.

The first data that was presented on COVID-19 vaccination in Israel has surfaced and says that people treated with fingolimod and ocrelizumab struggle to make a B cell response. On the left graph below the dotted line and you don,t make a good antibody response. So good news for the clad lads…. Humoral immune response to COVID-19 mRNA vaccine in patients...

MS-COVID blood spot study update!

Many avid readers of the blog will remember the guest post from Sita a few weeks ago. As part of her elective placement I asked her to look at some of the early data from people taking part in the COVID blood spot study, and she has written a blog post below talking about what she found. This is very timely, as in a BartsMS advisory group meeting this morning I was reminded of the importance of...

Ocrelizumab removing infection protection in a small number of people

Alba Suárez EM, Tallón Barranco A, Puertas Muñoz I, Chamorro Hernández B, Robles Marhuenda Á. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab. Neurologia. 2021 13:S0213-4853(21)00026-8. Late-onset neutropaenia (loss of neutrophils which are our first line against infection) is defined as an absolute neutrophil count of <1.5×103cells/μL starting>4 weeks...

Translate

Categories

Recent Posts

Recent Comments

Archives